Colorectal adenocarcinoma is the most common type of cancer affecting the colon and rectum, and understanding treatment options is essential for anyone facing this diagnosis. While the journey through colorectal cancer can be challenging, advances in medical care mean that patients today have access to both well-established therapies and promising new approaches being tested in clinical research.

Understanding Your Treatment Path

When you receive a diagnosis of colorectal adenocarcinoma, also known simply as colon cancer, one of the first things your medical team will discuss with you is your treatment plan. This type of cancer begins in the large intestine when cells in the inner lining of your colon or rectum start growing out of control. The approach to treating this cancer depends on several important factors that are unique to each person.

The stage of your cancer plays a major role in determining which treatments will be most helpful. Doctors look at how far the cancer has spread—whether it’s still confined to the innermost layer of your colon wall, whether it has moved through other layers of tissue and muscle, or whether it has traveled to lymph nodes or other parts of your body. Early-stage cancers that are caught before they spread often have a better outlook and may require less intensive treatment than cancers found at more advanced stages.^[1]

Your overall health and any other medical conditions you have also influence which treatments are appropriate for you. For instance, certain chemotherapy drugs or surgical procedures may not be suitable for someone with heart problems or other health concerns. Your personal preferences matter too—understanding the potential benefits and side effects of different options helps you and your doctors make decisions that align with your goals and values.^[8]

Medical societies and cancer organizations have developed guidelines based on years of research to help doctors choose the best standard treatments. These clinical guidelines (recommendations from expert medical groups) outline proven therapies that have been shown to work in large groups of patients. At the same time, researchers are constantly working on new treatments that may be even more effective. These experimental approaches are tested in clinical trials (research studies with volunteer patients) to determine if they’re safe and if they work better than existing options.^[5]

Standard Treatment Approaches

The three main ways that doctors treat colorectal adenocarcinoma have been used for many years and are considered standard care. These include surgery, chemotherapy, and radiation therapy. Most patients receive a combination of these treatments rather than just one, and the order in which they’re given depends on the specifics of your cancer.^[1]

Surgery

Surgery is often the primary treatment for colorectal cancer, especially when the disease is detected early. The type of operation you need depends on where the cancer is located and how advanced it is. In some cases, a small cancer or polyp can be removed during a colonoscopy (a procedure where a flexible tube with a camera examines the inside of your colon). This is called a local excision and is only possible for very early-stage cancers that haven’t grown deep into the colon wall.^[1]

For larger or more advanced cancers, surgeons perform a bowel resection, which means removing the section of the colon or rectum that contains the cancer along with some surrounding healthy tissue and nearby lymph nodes. The remaining healthy ends of the bowel are then reconnected. This procedure can often be done using minimally invasive techniques with small incisions, which typically leads to faster recovery compared to traditional open surgery.^[12]

Sometimes, particularly with rectal cancers or very advanced colon cancers, the surgeon may need to create a colostomy or ileostomy. This means bringing part of the intestine through an opening in the abdominal wall so that stool can leave the body and collect in a bag worn outside. For many patients, this is temporary while the bowel heals after surgery. However, in some cases, especially with very low rectal cancers, it may be permanent.^[12]

Chemotherapy

Chemotherapy uses powerful drugs to kill cancer cells or stop them from growing. These medications travel through your bloodstream to reach cancer cells throughout your body, which is why chemotherapy is considered a systemic therapy (treatment that affects the whole body). Doctors commonly recommend chemotherapy for colorectal cancer patients in several situations: after surgery to eliminate any remaining cancer cells, before surgery to shrink a tumor, or as the main treatment when cancer has spread to other organs.^[12]

Several different chemotherapy drugs are used to treat colorectal adenocarcinoma. The most common ones include 5-fluorouracil (often called 5-FU), which interferes with cancer cells’ ability to make new DNA, and capecitabine, an oral medication that the body converts into 5-FU. Other frequently used drugs include oxaliplatin and irinotecan, which work by damaging the DNA inside cancer cells so they cannot divide and grow.^[16]

Doctors often give these drugs in combinations rather than alone because using multiple agents together tends to work better than single drugs. A common regimen called FOLFOX combines 5-FU, leucovorin (a vitamin that makes 5-FU work better), and oxaliplatin. Another combination called FOLFIRI uses 5-FU, leucovorin, and irinotecan. Your oncologist will choose the specific combination based on factors like your cancer’s characteristics, your overall health, and whether you’ve received chemotherapy before.^[16]

Chemotherapy is typically given in cycles—a period of treatment followed by a rest period to allow your body to recover. A cycle might last two or three weeks, and you may receive multiple cycles over several months. Some chemotherapy drugs are given through an IV in a clinic or hospital, while others can be taken as pills at home. The total duration of chemotherapy varies widely but often lasts three to six months for patients receiving treatment after surgery.^[12]

Like all powerful medications, chemotherapy can cause side effects because these drugs affect fast-growing normal cells as well as cancer cells. Common side effects include fatigue, nausea and vomiting, diarrhea or constipation, mouth sores, hair loss, and increased risk of infections because chemotherapy can lower your white blood cell count. Oxaliplatin can cause neuropathy (nerve damage that causes numbness, tingling, or pain in hands and feet), which may be temporary or long-lasting. Not everyone experiences all these side effects, and doctors have many medications to help prevent or reduce them.^[16]

Radiation Therapy

Radiation therapy uses high-energy beams to kill cancer cells by damaging their DNA. It’s more commonly used for rectal cancer than colon cancer because the rectum is located in a fixed position in the pelvis, making it easier to target precisely with radiation beams. For colon cancer higher up in the abdomen, the bowel moves around, which makes it harder to aim radiation accurately.^[16]

When radiation is used for rectal cancer, it’s often given before surgery to shrink the tumor and make it easier to remove completely. This approach, called neoadjuvant therapy (treatment given before the main treatment), may also increase the chances of preserving the sphincter muscles that control bowel movements, potentially avoiding the need for a permanent colostomy. Radiation can also be given after surgery to eliminate any cancer cells that might remain in the area where the tumor was removed.^[16]

Radiation is frequently combined with chemotherapy, an approach called chemoradiation. The chemotherapy drugs make the cancer cells more sensitive to radiation, which can make the treatment more effective. Side effects of radiation to the pelvis can include fatigue, skin irritation in the treatment area, diarrhea, bladder irritation, and sexual dysfunction. Most of these side effects improve after treatment ends, though some people experience long-term bowel changes.^[16]

Targeted Therapy

Targeted therapies are newer drugs that attack specific features of cancer cells while causing less harm to normal cells compared to traditional chemotherapy. These medications are often used for advanced colorectal cancer that has spread to other parts of the body. Targeted therapies work in different ways depending on which molecules they’re designed to block.^[16]

One group of targeted drugs blocks blood vessel growth, which tumors need to get nutrients and oxygen. Bevacizumab is a monoclonal antibody (a laboratory-made protein that mimics immune system antibodies) that targets a protein called VEGF, which tumors use to create new blood vessels. By blocking VEGF, bevacizumab can slow tumor growth. Another drug in this category is ramucirumab, which works similarly by targeting the receptor that VEGF binds to on blood vessel cells.^[12]

Another type of targeted therapy blocks growth signals that cancer cells use to divide and multiply. Cetuximab and panitumumab are monoclonal antibodies that target a protein called EGFR found on the surface of many colorectal cancer cells. These drugs only work for patients whose tumors have normal versions of certain genes called RAS and BRAF—your doctor will test your tumor tissue to see if these medications are appropriate for you. Blocking EGFR can stop cancer cells from growing and may help chemotherapy work better.^[16]

Side effects of targeted therapies differ from traditional chemotherapy side effects. Drugs that block blood vessel growth can cause high blood pressure, fatigue, bleeding problems, and rarely, serious issues like blood clots or bowel perforations. EGFR-blocking drugs often cause skin rashes and other skin problems because EGFR is also found on normal skin cells. They can also cause diarrhea and, less commonly, serious allergic reactions during infusion.^[16]

Immunotherapy

Immunotherapy is a treatment approach that helps your own immune system recognize and attack cancer cells. While the immune system normally fights infections and abnormal cells, cancer cells have developed ways to hide from immune surveillance. Immunotherapy drugs can remove these disguises or boost the immune system’s ability to find and destroy cancer.^[16]

For colorectal cancer, immunotherapy works particularly well in patients whose tumors have a specific characteristic called high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR). These terms mean that the tumor cells have problems with the system that normally repairs mistakes when DNA is copied. This leads to many mutations in the cancer cells, making them easier for the immune system to recognize as abnormal. About 5 to 15 percent of colorectal cancers have this feature.^[17]

The immunotherapy drugs approved for colorectal cancer are called checkpoint inhibitors because they block proteins that act as “checkpoints” or brakes on the immune system. Pembrolizumab, nivolumab, and dostarlimab block a checkpoint protein called PD-1, while ipilimumab blocks another checkpoint called CTLA-4. By releasing these brakes, the immune system can attack cancer cells more effectively. Sometimes doctors use a combination of two checkpoint inhibitors, such as nivolumab plus ipilimumab, for better results.^[17]

Before receiving immunotherapy, your doctor will test your tumor tissue to determine if it has MSI-H or dMMR characteristics. This testing is crucial because immunotherapy generally doesn’t work well for colorectal cancers that don’t have these features. When immunotherapy does work for MSI-H tumors, the results can be quite impressive, with tumors shrinking significantly or even disappearing in some patients.^[17]

The side effects of immunotherapy are different from chemotherapy side effects because they’re caused by an overactive immune system rather than direct damage to cells. The immune system might start attacking normal organs, causing inflammation in the lungs, liver, intestines, hormone glands, or other tissues. These side effects can range from mild to severe and may require treatment with steroids or other immune-suppressing drugs. Common side effects include fatigue, skin rash, diarrhea, and changes in hormone levels. Most side effects can be managed if caught early, which is why regular monitoring is important during immunotherapy treatment.^[17]

Promising Treatments in Clinical Trials

While standard treatments have helped many colorectal cancer patients, researchers continue searching for new approaches that might work better or cause fewer side effects. These experimental treatments are tested in clinical trials, which are carefully designed research studies that evaluate whether new therapies are safe and effective. Participating in a clinical trial gives patients access to cutting-edge treatments before they become widely available, and it also contributes to medical knowledge that can help future patients.^[8]

Clinical trials happen in phases, each designed to answer specific questions. Phase I trials are the first tests of a new treatment in humans and focus primarily on safety—researchers want to know what dose can be given safely and what side effects occur. These trials usually involve small numbers of patients. Phase II trials include more patients and test whether the treatment actually works against the cancer—do tumors shrink or stop growing? Phase III trials are large studies that compare the new treatment to the current standard treatment to see which works better. If a Phase III trial shows that a new treatment is more effective or safer than existing options, it may be approved by regulatory agencies like the FDA for general use.^[8]

Novel Immunotherapy Approaches

Beyond the checkpoint inhibitors already approved for MSI-H colorectal cancers, researchers are testing new immunotherapy strategies that might help patients whose tumors don’t have this characteristic. Since checkpoint inhibitors don’t work well for most colorectal cancers, scientists are exploring ways to make these tumors more recognizable to the immune system or to overcome their resistance to immunotherapy.^[13]

One promising approach involves combining immunotherapy with other treatments. Clinical trials are testing checkpoint inhibitors given together with chemotherapy, targeted drugs, or radiation therapy. The idea is that these other treatments might damage cancer cells in ways that make them easier for the immune system to detect and attack. Early results from some of these combination studies have shown encouraging signs that tumors respond better when multiple approaches are used together.^[13]

Researchers are also investigating cancer vaccines, which are different from vaccines that prevent diseases like measles or COVID-19. Instead, cancer vaccines are designed to teach the immune system to recognize and attack cancer cells that are already present in the body. These vaccines might contain pieces of proteins found on colorectal cancer cells or use the patient’s own cancer cells that have been modified in the laboratory. While cancer vaccines for colorectal cancer are still largely experimental, some early-phase trials have shown that they can trigger immune responses against tumors.^[13]

Targeted Therapies for Specific Mutations

As scientists learn more about the genetic changes that drive colorectal cancer growth, they’re developing targeted drugs designed to block these specific abnormalities. This approach is sometimes called precision medicine because the treatment is precisely matched to the molecular characteristics of each patient’s tumor. Before receiving these therapies, patients need genetic testing of their tumor tissue to identify which mutations are present.^[13]

One area of intense research involves cancers with mutations in genes called BRAF and KRAS. About 10 percent of colorectal cancers have a BRAF mutation, and these tumors tend to be more aggressive and harder to treat. New drugs that specifically target the abnormal BRAF protein are being tested, often in combination with other drugs that block related growth pathways. Some of these combinations have shown promise in clinical trials and may eventually become standard treatment options.^[13]

KRAS mutations are even more common, occurring in about 40 percent of colorectal cancers. For many years, KRAS was considered “undruggable”—scientists couldn’t figure out how to make a medication that would block this protein effectively. Recently, however, researchers have developed drugs that can target specific forms of mutated KRAS. These drugs are currently being tested in clinical trials for colorectal cancer patients whose tumors have certain KRAS mutations. The results from early trials have been encouraging, suggesting that some patients benefit from these new KRAS-blocking drugs.^[13]

Tumor-Infiltrating Lymphocyte Therapy

A highly personalized form of immunotherapy being studied is called tumor-infiltrating lymphocyte therapy or TIL therapy. This approach involves removing a sample of the patient’s tumor through surgery or biopsy and isolating the immune cells that have naturally migrated into the tumor. These immune cells are already trying to fight the cancer but may be overwhelmed or suppressed. In the laboratory, scientists grow millions of copies of these tumor-fighting cells and then infuse them back into the patient, potentially creating a powerful anti-cancer immune response.^[13]

TIL therapy is complex and time-consuming—it takes several weeks to grow enough cells in the laboratory. Before receiving the infusion, patients undergo chemotherapy to temporarily reduce their normal immune cells, making room for the tumor-fighting cells to work more effectively. While TIL therapy has shown remarkable results in treating melanoma and some other cancers, research on its use for colorectal cancer is still in earlier stages. Clinical trials are ongoing to determine whether this approach can help colorectal cancer patients.^[13]

Antibody-Drug Conjugates

Antibody-drug conjugates are an innovative class of medications that combine the targeting ability of monoclonal antibodies with the cancer-killing power of chemotherapy drugs. Think of them as “smart bombs”—the antibody portion acts like a guided missile that seeks out cancer cells bearing a specific protein on their surface, while the attached chemotherapy drug acts as the explosive payload that destroys the cancer cell once the antibody delivers it to its target.^[13]

This approach has advantages over traditional chemotherapy because the toxic drug is delivered directly to cancer cells rather than circulating throughout the entire body, which should reduce side effects on normal tissues. Researchers are testing several different antibody-drug conjugates for colorectal cancer in clinical trials. Each one targets a different protein that is more abundant on cancer cells than on normal cells. These trials are evaluating whether these new agents can shrink tumors that have stopped responding to standard treatments.^[13]

Combination Approaches and Sequencing Strategies

An important area of clinical research involves figuring out not just which drugs work, but how best to combine them and in what order to give them. Researchers are testing whether giving immunotherapy before surgery might help eliminate microscopic cancer cells that could lead to recurrence. Other trials are examining whether alternating between different types of chemotherapy or combining three or more drugs produces better results than standard two-drug combinations.^[13]

Clinical trials are also exploring maintenance therapy approaches, where patients who respond well to initial treatment continue receiving milder therapy to keep the cancer under control for as long as possible. This strategy treats advanced colorectal cancer more like a chronic disease that can be managed over time, similar to how conditions like diabetes or high blood pressure are controlled with ongoing medication.^[13]

Most Common Treatment Methods

• Surgery
  • Local excision during colonoscopy for early-stage cancers or polyps
  • Bowel resection removing the cancer-containing section of colon or rectum along with nearby lymph nodes
  • Minimally invasive surgical techniques using small incisions
  • Colostomy or ileostomy procedures when needed, which may be temporary or permanent
• Chemotherapy
  • 5-fluorouracil (5-FU) which interferes with cancer cell DNA production
  • Capecitabine, an oral form of chemotherapy converted to 5-FU in the body
  • Oxaliplatin which damages DNA inside cancer cells
  • Irinotecan which prevents cancer cells from dividing
  • FOLFOX combination regimen using 5-FU, leucovorin, and oxaliplatin
  • FOLFIRI combination using 5-FU, leucovorin, and irinotecan
  • Treatment given in cycles over several months, typically three to six months after surgery
• Radiation Therapy
  • High-energy beams targeting cancer cells in the rectum
  • Neoadjuvant radiation given before surgery to shrink tumors
  • Post-surgical radiation to eliminate remaining cancer cells
  • Chemoradiation combining radiation with chemotherapy drugs
• Targeted Therapy
  • Bevacizumab blocking VEGF to prevent blood vessel growth in tumors
  • Ramucirumab targeting VEGF receptors on blood vessel cells
  • Cetuximab and panitumumab blocking EGFR growth signals on cancer cells
  • Used primarily for advanced colorectal cancer that has spread
• Immunotherapy
  • Checkpoint inhibitors including pembrolizumab, nivolumab, and dostarlimab that block PD-1
  • Ipilimumab blocking the CTLA-4 checkpoint protein
  • Combination immunotherapy using nivolumab plus ipilimumab
  • Effective specifically for tumors with high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR)
  • Tumor testing required before treatment to determine MSI-H or dMMR status
• Clinical Trial Treatments
  • Novel immunotherapy combinations with chemotherapy, targeted drugs, or radiation
  • Cancer vaccines designed to train the immune system to attack cancer cells
  • Targeted drugs for BRAF mutations found in about 10 percent of colorectal cancers
  • New KRAS-targeting drugs for tumors with specific KRAS mutations
  • Tumor-infiltrating lymphocyte (TIL) therapy using patient’s own tumor-fighting immune cells
  • Antibody-drug conjugates combining targeted antibodies with chemotherapy drugs
  • Maintenance therapy strategies to manage cancer as a chronic condition